

Unaudited Interim

Consolidated Financial Statements

For the nine-month period ended February 28, 2015 and 2014

(In Canadian dollars, except number of shares)

Table of contents

Notice to readers	3
Statements of Financial Position	4
Statements of Comprehensive Loss	5
Statements of changes in equity	
	6
Statements of changes in equity	7
Statement of cash flows	8
Notes to Financial Statements	9-23

NOTICE TO READERS OF THE UNAUDITED INTERIM FINANCIAL STATEMENTS:

The unaudited interim financial statements of Affinor Growers Inc. for the nine-month period ended February 28, 2015 have not been reviewed by the Company's external auditors.

(s) Sébastien Plouffe,

Président, chief executive officer, Director

(s) Pierre C. Miron

Chief Financial Officer, Director

	February 28, 2015 (unaudited)	May 31, 2014 (audited)
	\$	\$
ASSETS		
CURRENT ASSETS		
Cash	64,198	1,944,644
Other receivables (note 8)	77,520	44,588
Investments (note 9)	135,000	-
Prepaid expenses	296,731	170,613
	573,449	2,159,845
NON CURRENT		
Exploration and evaluation assets (note 10)	1	4
Property equipment (note 11)	1,155,874	5,000
Intangibles assets (note 12)	702,635	-
Investment accounted for using the equity method (note 13)	644,929	-
TOTAL ASSETS	3,076,888	2,164,849
LIABILITIES		
CURRENT LIABILITIES		
Trade and other payables (note 14)	338,298	249,850
EQUITY		
Share capital (note 15)	15,507,907	11,948,091
Warrants	746,129	951,093
Accumulated other comprehensive income	(211,050)	-
Contributed surplus	4,823,395	3,588,305
Deficit	(18,127,791)	(14,572,490)
TOTAL EQUITY	2,732,201	1,914,999
TOTAL LIABILITIES AND EQUITY	3,076,888	2,164,849

	For the three-month period ended February 28			e-month period led February 28
	2015	2014	2015	2014
	\$	\$	\$	\$
REVENUE				
Sales	190,262	-	285,714	-
EXPENSES				
Registration and information to shareholders	15,243	5,412	56,007	17,503
Professional fees and consulting fees	335,576	16,944	1,370,356	39,254
Employee benefit expenses	52,645	-	147,116	-
Management fees	75,000	83,250	225,000	133,808
Share-based payments	184,452	2 806	1,407,117	16,363
Amortization	11,479	-	26,300	-
Other operation expenses	(32,829)	12,359	260,796	35,676
	641,566	120,771	3,492,692	242,604
OPERATING LOSS	(451,304)	(120,771)	(3,206,978)	(242,604)
Interest on convertible debenture	-	-	-	(20 783)
Loss on dilution from an investment accounted for using the equity method	(46,109)	-	(62,911)	-
Gain on debt settlement	-	-	-	9,545
Gain on disposal of investments	-	-	20,760	-
Write-off of investment	(313,508)		(313,508)	
Other revenue	1,210	<u>-</u>	7,336	72
LOSS BEFORE INCOME TAXES	(809,711)	(120,771)	(3,555,301)	(253,770)
Deferred income tax	-	-	-	36,880
NET LOSS AND TOTAL COMPREHENSIVE LOSS FOR THE PERIOD	(809,711)	(120,771)	(3,555,301)	(216,890)
Other comprehensive income (loss)				
Available for sale financial assets	(141,000)	-	(211,050)	-
Net change in faire value for the period	(141,000)	-	(211,050)	-
Total comprehensive loss for the period	(950,711)	(120,771)	(3,766,351)	(216,890)
Basic and diluted loss per share (note 18)	(0,012)	(0.003)	(0,056)	(0.007)
Weighted average number of shares in circulation for basic and diluted earnings per share	65,614,077	35,437,262	63,660,931	33,121,020

	Number of shares	Share Capital	Warrants	Contributed surplus	Accumulated other comprehensive income	Deficit	Total Equity
		\$	\$	\$	\$	\$	\$
Balance as at June 1, 2014	60,953,898	11,948,091	951,093	3,588,305	-	(14,572,490)	1,914,999
Private placement	700,000	63,033	41,967				105,000
License agreement	1,388,888	723,888	-	-	-	-	723,888
Acquisition of 49 % interest on private company	949,613	541,940	-	-	-	-	541,940
Share-based payments	-	-	-	1,407,117	-	-	1,407,117
Options exerciced	1,470,000	406,527	-	(172,027)	-	-	234,500
Consultant and management services	1,903,554	493,526	-	-	-	-	493,526
Warrants exerciced	2,655,000	1,308,932	(246,931)	-	-	-	1,062,001
Brokers warrants exerciced	54,925	21,970	-	-	-	-	21,970
Shares cancelled	(2,500,000)	-	-	-	-	-	
Net loss for the period	-	-	-	-	-	(3,555,301)	(3,555,301)
Net change in fair value of Available-for sale financial assets	-	-	-	-	(211,050)	-	(211,050)
Balance as at February 28, 2015	67,578,878	15,507,907	746,129	4,823,395	(211,050)	(18,127,791)	2,738,590

AFFINOR GROWERS INC. Consolidated Statement of change in Equity For the nine-month period ended February 28, 2014 (Unaudited, in Canadian dollars)

	Number of	Chave Conitel	Share Capital subscription received	Mayanta	Contributed	Definit	Tatal Facility
	shares	Share Capital \$	received \$	Warrants \$	surplus \$	Deficit \$	Total Equity \$
Balance as at June 1, 2013	19,655,609	5,552,266	16,500	46,866	633,762	(6,395,687)	(146,293)
Private placement	8,583,333	128,750	(16,500)	-	-	-	112,250
Acquisition of mining properties	985,000	14,775	-	-	-	-	14,775
Debt settlement	6,213,320	348,386	-	-	(186,031)	-	162,355
Expired warrants	-	-	-	(46,866)	46,866	-	-
Share-based payments	<u>-</u>	-	<u>-</u>	-	16,363	-	16,363
Net loss for the period	-	-	-	-	-	(216,890)	(216,890)
Balance as at February 28, 2014	35,437,262	6,044,177	-	-	510,960	(6,612,577)	(57,440)

	For the three-month period ended February 28			nine-month period ended February 28
	2015	2014	2015	2014
	\$	\$	\$	5
OPERATING ACTIVITIES				
Net loss	(809,711)	(120,771)	(3,555,301)	(216,889)
Sales	(278,564)	-	(285,139)	-
Interest on convertible debenture	-	-	-	20,783
Gain on debt settlement	-	-	-	(9,546)
Loss on dilution from an investment accounted for using the equity method	46,109	-	62,911	-
Net change in working capital (note 18)	(292,349)	102,284	100,163	99,942
Deferred income tax	-	-	-	(36,880)
Other operation expenses	-	-	3	-
Amortization	11,479	-	26,300	-
Consulting and professional fees	61,875	-	307,901	-
Gain on disposal of investments	-	-	(20,760)	-
Share-based payment	184,452	2,806	1,407,117	16,363
Cash flows from operating activities	(1,076,709)	(15,681)	(1,956,805)	(126,227)
INVESTING ACTIVITIES				
Investments accounted for using the equity method	677,873	-	(165,900)	-
Investments	-	-	(25,290)	-
Property and equipments	(116,380)	-	(1,155,921)	-
Mining properties	-	-	-	(10,365)
Cash flows from investing activities	561,493		(1,347,111)	(10,365)
FINANCING ACTIVITIES				
Proceeds from issue of share capital	180,000	-	1,423,470	112,250
Cash flows from financing activities	180,000	-	1,423,470	112,250
Net change in cash	(335,216)	(15,681)	(1,880,446)	(24,342)
Cash beginning of the period	399,414	17,576	1,944,644	26,237
Cash end of the period	64,198	1,895	64,198	1,895

Notes to financial statements

For the nine-month periods ended February 28, 2015 and 2014

(Unaudited, in Canadian dollars)

1. NATURE OF ACTIVITIES

As of May 23, 2014, Affinor Growers (hereafter "the Company") was specialized in exploration of gold mineral sites located in Canada and South America, since that date, the Company is focusing on the agriculture industry within North America.

In May 2014, the Company decided to change its name to Affinor Growers inc. This decision aims to better reflect the mission of the Company that is to produce strawberries and other crops such as romaine lettuce and herbs and to produce and sell medical marijuana.

2. GOING CONCERN ASSUMPTION

The consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS) on the basis of the assumption of going concern, meaning the Company will be able to realize its assets and discharge its liabilities in the normal course of operations.

Since the Company has not yet found a property that contains economically exploitable mineral deposits, the Company did not generate income or cash flows from operations to date and in light of operating losses incurred this year and in past nine-month period, there is a significant doubt about the Company's ability to continue as a going concern.

The Company's ability to continue as a going concern is dependent upon the support of its suppliers and creditors and obtaining additional financing necessary to continue the exploration of its mineral properties and to generate income or cash flows from operations from product and sale of medical marijuana and the other major crops such as romaine lettuce and strawberries. Although the Company has managed to fund its exploration programs in the past, there is no guarantee that it whit manage to additional financing in the future.

The carrying amounts of assets and liabilities, revenues and expenses and classification if the going concern assumption was not be appropriate in statement of financial position has not been adjusted as would be requested. These adjustments could be material.

3. GENERAL INFORMATION AND STATEMENT OF COMPLIANCE WITH IFRS

The consolidated financial statements of the Company have been prepared in accordance with International Financial Reporting Standards (IFRS).

Affinor Growers inc. is the ultime parent Company of the group.

Affinor Growers Inc. is incorporated under *Canada business corporation act*. The address of the Company registered office and its principal place of business is 410 St-Nicolas street, suite 236, Montreal, Quebec. Its shares are listed on the Canadian Securities Exchange (CSE), the Frankfurt Stock Exchange and the OTC QB Exchange.

The consolidated financial statements for the reporting nine-month period ended February 28, 2015 (including comparatives) were approved and authorized for issue by the Board of Directors on April 29, 2015.

4. CHANGES IN ACCOUNTING POLICIES

4.1 New and revised standards that are effective

A number of new and revised standards are effective for annual periods beginning on or after January 1, 2013. Information on new standards that are relevant for the Company is presented below.

IFRS 13 Fair Value Measurement

IFRS 13 clarifies the definition of fair value and provides related guidance and enhanced disclosures about fair value measurements. It does not affect the items that are required to be fair-valued.

The scope of IFRS 13 is broad and applies for both financial and non-financial items for which other IFRS require or permit fair value measurements or disclosures about fair value measurements except in certain circumstances.

IFRS 13 applies prospectively for annual periods beginning on or after January 1, 2013. Its disclosure requirements need not be applied to comparative information in the first year of application.

Management reviewed its valuation methodologies and the application of the new standard did not have any effect on the fair value measurement.

IFRS 10 Consolidated Financial Statements

IFRS 10 supersedes IAS 27 Consolidated and Separate Financial Statements (IAS 27) and SIC 12 Consolidation – Special Purpose Entities. IFRS 10 revises the definition of control and provides extensive new guidance on its application.

These new requirements have the potential to affect which of the Company's investees are considered to be subsidiaries and therefore to change the scope of consolidation. The requirements on consolidation procedures, accounting for changes in non-controlling interests and accounting for loss of control of a subsidiary are unchanged.

Management has reviewed its control assessments in accordance with IFRS 10 and has concluded that there is non effect on the classification (as subsidiaries or otherwise) of any of the Company's investees held during the period or comparative periods covered by these consolidated financial statements.

IFRS 12 Disclosure of Interests in Other Entities

IFRS 12 integrates and makes consistent the disclosure requirements for various types of investments, including unconsolidated structured entities. It introduces new disclosure requirements about the risks to which an entity is exposed from its involvement with structured entities.

Notes to financial statements

For the nine-month periods ended February 28, 2015 and 2014

(Unaudited, in Canadian dollars)

4. CHANGES IN ACCOUNTING POLICIES (continued)

4.2 Standards, amendments and interpretations to existing standards that are not yet effective and have not been adopted early by the Company.

At the date of authorization of these consolidated financial statements, certain new standards, amendments and interpretations to existing standards have been published but are not yet effective and have not been adopted early by the Company.

Management anticipates that all of the pronouncements will be adopted in the Company's accounting policies for the first period beginning after the effective date of each pronouncement. Information on new standards, amendments and interpretations that are expected to be relevant to the Company's consolidated financial statements is provided below. Certain other new standards and interpretations have been issued but are not expected to have an impact on the Company's consolidated financial statements.

IFRS 9 Financial Instruments (IFRS 9)

In July 2014, the IASB published IFRS 9 which replaces IAS 39 Financial Instruments: Recognition and Measurement (IAS)39). IFRS 9 introduces improvements which include a logical model for classification and measurement of financial assets, a single, forward-looking "expected loss" impairment model and a substantially-reformed approach to hedge accounting. IFRS 9 is effective for annual reporting periods beginning on or after January 1, 2018. Earlier application is permitted. The Company has yet to assess the impact of this new standard on its consolidated financial statements

5. SUMMARY OF ACCOUNTING POLICIES

5.1 Overall considerations

The significant accounting policies and measurement bases that have been applied in the preparation of these consolidated financial statements are summarized below.

The Company's financial statements consolidate those of the Company, Affinor Analytics LLC. The parent controls a subsidiary if it is exposed, or has rights, to variable returns from its involvement with the subsidiary and has the ability to affect those returns through its power over the subsidiary. The Company's subsidiaries are 100% owned by Affinor.

All transactions and balances between companies are eliminated upon consolidation, including unrealized gains and losses on transactions between group companies.

Amounts reported in the financial statements of subsidiary have been adjusted where necessary to ensure consistency with the accounting policies adopted by the Company.

Profit and loss and other comprehensive income of subsidiaries acquired or disposed of during the reporting annual period are recognized from the effective date of the acquisition, or up to the effective date of disposal, as applicable.

5.3 Basis of evaluation

These consolidated financial statements are prepared using the historical cost method.

5.4 Financial Instruments

Assets and liabilities are recognized when the Company becomes a party to the contractual provisions of the financial instrument.

Financial assets are derecognized when the contractual rights to cash flows from the financial asset expire, or when the financial asset and all substantial risks and rewards are transferred.

A financial liability is derecognized when extinguishment, termination, cancellation or expiration.

Assets and liabilities are initially measured at fair value plus transaction costs.

Assets and financial liabilities are subsequently measured as described below.

Financial assets

For the purpose of subsequent measurement, financial assets are classified in various categories at the time of initial recognition.

The category determines the subsequent measurement method and accounting in either earnings or in other comprehensive income of revenues and expenses. All income and expenses related to financial assets recognized in earnings are presented in the financial expenses or financial products, if applicable.

All the financial assets of the Company are classified as loans and receivables. Loans and receivables are non derivative financial assets with fixed or determinable payments that are not quoted in an active market. After initial recognition they are measured at amortized cost using the method of effective interest rate, less a provision for impairment. Discounting is omitted if its effect is not significant. Cash and other receivables (except for taxes receivable) fall into this category of instruments Financial.

Impairment of financial assets

All financial assets except those at fair value through profit or loss are tested for impairment at each balance sheet date. Financial assets are impaired when there is objective evidence that a financial asset or group of financial assets suffered an impairment loss.

Objective evidence of impairment could include:

- Significant financial difficulty on the part of the issuer or obligor;
- A breach of contract such as a failure to pay interest or principal;
- Increasing the likelihood of bankruptcy or other financial reorganization of the borrower.

Notes to financial statements

For the nine-month periods ended February 28, 2015 and 2014

(Unaudited, in Canadian dollars)

5. SUMMARY OF ACCOUNTING POLICIES (continued)

5.4 Financial Instruments (continued)

Individually significant receivables are considered for impairment when they are past due or when other objective evidence is received that a specific counterparty will default. Impairment of receivables is presented in profit or loss within Other operating expenses, if applicable.

Financial liabilities

Financial liabilities of the Company include trade and other payables and convertible debentures.

Financial liabilities are subsequently measured at amortized cost using the method of effective interest rate.

5.5 Business combinations under common control

Business combinations under common control are accounted for prospectively from the date the Company obtains the ownership interest using the predecessor values method. Whereby, assets and liabilities are recognized upon consolidation at their carrying amount recorded in the books of the acquired company.

5.6 Basic and diluted loss per share

Basic loss per share is calculated by dividing the loss attributable to common shareholders of the parent Company by the weighted average number of common shares outstanding during the year. Diluted loss per share is calculated by adjusting the loss attributable to ordinary equity holders of the parent Company and the weighted average number of common shares outstanding, the effects of all dilutive potential ordinary shares, which include share options warrants and the convertible debenture. It is assumed that the dilutive potential ordinary shares were converted into ordinary shares at beginning of the period or the date of issue of potential ordinary shares, if later.

To calculate diluted loss per share, an entity shall assume dilutive conversion options, dilutive warrants, and convertible debenture were exercised.

The assumed proceeds from these instruments shall be regarded as having been received from issuance of common shares at the average market price of common shares during the period

5.7 Exploration and evaluation assets

All costs of acquiring mineral rights are recognized as exploration and evaluation assets. These assets are recognized as intangible assets and are carried at cost less any accumulated impairment losses. No depreciation expenses are recognized for these assets during the exploration and evaluation phase. Whenever a mining property is considered no longer viable, or is abandoned, the capitalized amounts are written down to their recoverable amounts; the difference is then immediately recognized in profit or loss. The recoverable amount of an asset is the higher of its fair value less cost to sell and its value in use. To determine the value in use, management estimates expected future cash flows from each asset, and then determines an appropriate interest rate for the calculation of the expected present value of the cash flows.

Although the Company has taken steps to verify title to the mining properties in which it holds an interest, in accordance with industry practices for the current stage of exploration and development of such properties, these procedures do not guarantee the validity of the Company's titles. Property titles may be subject to unregistered prior agreements and non-compliance with regulatory requirements.

5.8 Property and equipment

Property and equipment are held at cost less accumulated depreciation and accumulated impairment losses.

Cost includes all costs incurred initially to acquire or construct an item of property and equipment, costs directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management and costs incurred subsequently to add to or replace part thereof.

Depreciation is recognized on a straight-line basis to write down the cost to its estimated residual value, with a constant charge over the useful life of the asset. The periods generally applicable are as follows:

Computer equipment30% declining balanceOffice equipment20% declining balanceLand-Building25 years

The residual value, depreciation method and useful life of each asset are reviewed at least at each financial year-end.

The carrying amount of an item of property and equipment is derecognized upon disposal or when no future economic benefits are expected from its use or disposal. The gain or loss arising from the derecognition of an item of property and equipment is included in profit or loss when the item is derecognized.

5.9 Intangible assets

License

Intangible assets that are acquired by the Company and have finite useful lives are measured at cost less accumulated amortization and accumulated impairment losses.

intangible assets are amortized annually	on a straight-line basis at the following rates	

Useful life
20 years

AFFINOR GROWERS INC. Notes to financial statements For the nine-month periods ended February 28, 2015 and 2014 (Unaudited, in Canadian dollars)

5. SUMMARY OF ACCOUNTING POLICIES (continued)

5.10 Impairment of exploration and evaluation assets and property and equipment

For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are largely independent cash inflows (cash-generating units). As a result, some assets are tested individually for impairment and some are tested at a cash-generating unit level.

Whenever events or changes in circumstances indicate that the carrying amount may not be recoverable, an asset or cash-generating unit is reviewed for impairment.

Impairment reviews for exploration and evaluation assets are carried out on a project-by-project basis, with each project representing a potential single cash generating unit. An impairment review is undertaken when indicators of impairment arise, but typically when one of the following circumstances apply:

- the right to explore the areas has expired or will expire in the near future with no expectation of renewal;
- no further exploration or evaluation expenditures in the area are planned or budgeted;
- no commercially viable deposits have been discovered, and the decision has been made to discontinue exploration in the area;
- sufficient work has been performed to indicate that the carrying amount of the expenditure carried as an asset will not be fully recovered.

Additionally, when technical feasibility and commercial viability of extracting a mineral resource are demonstrable, the exploration and evaluation assets of the related mining property are tested for impairment before these items are transferred to property and equipment.

An impairment loss is recognized in profit or loss for the amount by which the asset's or cash-generating unit's carrying amount exceeds its recoverable amount. The recoverable amount of an asset or a cash-generating unit is the higher of its fair value less cost to sell and its value in use

An impairment loss is reversed if the asset's or cash-generating unit's recoverable amount exceeds its carrying amount.

5.11 Provisions, Contingent Liabilities and Contingent Assets

Provisions are recognized when present obligations as a result of a past event will probably lead to an outflow of economic resources from the Company and amounts can be estimated reliably. Timing or amount of the outflow may still be uncertain. Provisions are measured at the estimated expenditure required to settle the present obligation, based on the most reliable evidence available at the reporting date, including the risks and uncertainties associated with the present obligation. Provisions are discounted when the time value of money is significant.

The Company's operations are governed by government environment protection legislation. Environmental consequences are difficult to identify in terms of amounts, timetable and impact. As of the reporting date, management believes that the Company's operations are in compliance with current laws and regulations. Site restoration costs currently incurred are negligible. When the technical feasibility and commercial viability of extracting a mineral resource have been demonstrated, a restoration provision will be recognized in the cost of the mining property when there is constructive commitment that has resulted from past events, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and the amount of the obligation can be measured with sufficient reliability.

In those cases where the possible outflow of economic resources as a result of present obligations is considered improbable or remote, no liability is recognized, unless it was assumed in the course of a business combination.

All provisions are reviewed at each reporting date and adjusted to reflect the current best estimate. The Company has no provisions as at February 28, 2015 and 2014.

5.12 Income taxes

Tax expense recognized in profit or loss comprises the sum of deferred tax and current tax not recognized directly in equity.

Current income tax assets and/or liabilities comprise those obligations to, or claims from, fiscal authorities relating to the current or prior reporting periods, that are unpaid at the reporting date. Current tax is payable on taxable profit, which differs from profit or loss in the consolidated financial statements.

Calculation of current tax is based on tax rates and tax laws that have been enacted or substantively enacted by the end of the reporting period.

However, since the Company has no taxable income, tax expense recognized in profit or loss is currently comprised only of deferred tax.

Deferred tax is calculated using the liability method on temporary differences between the carrying amounts of assets and liabilities and their tax base. However, the deferred tax is not recognized at the time of initial recognition of goodwill or at the time of initial recognition of an asset or liability, unless the transaction giving rise thereto is a grouping of business or has an impact on accounting or taxable profit.

Deferred tax assets or liabilities are calculated, without discounting, according to tax rates that are expected to apply during their respective period of realization when these rates are substantively enacted by the end of the period presentation of financial information.

The deferred tax assets are recognized to the extent that it is probable that they will offset future taxable income.

Deferred tax liabilities are always provided in full.

Assets or deferred tax liabilities are offset only when the Company has the right and intention to offset assets or tax liabilities arising from the same tax authorities.

Changes in deferred tax assets or liabilities are recognized in profit or loss as deferred tax, unless they concern items that have been recognized directly in equity, in which case the deferred tax matching is also recognized in equity.

Notes to financial statements

For the nine-month periods ended February 28, 2015 and 2014

(Unaudited, in Canadian dollars)

5. SUMMARY OF ACCOUNTING POLICIES (continued)

5.12 Income taxes (continued)

Share capital

Proceeds from the issuance of common shares are classified as share capital. Issue costs directly attributable to additional shares and warrants are deducted from equity products during the period when these transactions took place, net of any underlying income tax benefit from these issue costs.

5.13 Equity

If shares are issued when options or warrants are exercised or when the conversion option of the convertible debenture is exercised, the share capital account also comprises the compensation costs or the equity portion of the convertible debenture previously recorded in contributed surplus or in warrants

Unit placements

Proceeds from unit placements are allocated proportionately between shares and warrants according to their respective fair values.

Share capital subscription received

Share capital subscription received includes amounts received for a share capital subscription for which the shares are not yet issued.

Warrants

Warrants include charges related to warrants. When warrants are exercised, the related compensation cost is transferred to share capital.

Contributed surplus

Contributed surplus includes expenses related to share options until the exercise of these options, the equity portion of the convertible debenture until the exercise of the conversion option and broker's warrants.

Deficit

Deficit includes all current and prior period retained profit or loss

5.14 Share-based Payments

The Company operates a share based payments plan for administrators, staff and advisors who qualify. No plan of the Company has the option of cash settlement.

All goods and services received in exchange for the granting of share-based payments are measured at fair value, unless that fair value cannot be estimated reliably. If the Company cannot estimate reliably the fair value of the goods or services received, the fair value is determined indirectly by reference to the fair value of equity instruments granted. This fair value is measured at grant date.

The share-based payments are ultimately recognized in the profit or loss with a corresponding credit to contributed surplus in shareholders' equity.

The expense is allocated over the vesting period, based on the best available estimate of the number of share options expected to vest. Estimates are subsequently revised if there is any indication that the number of share options expected to vest differs from previous estimates. Any cumulative adjustment prior to vesting is recognized in the current period. No adjustment is made to any expense recognized in prior period if share options ultimately exercised are different to that estimated on vesting.

6. JUDGEMENTS, ESTIMATES AND ASSUMPTIONS

In preparing the consolidated financial statements, management makes a number of judgments, estimates and assumptions regarding the recognition and measurement of assets, liabilities, revenues and expenses.

Actual results may differ from the judgments, estimates and assumptions made by management and they will rarely be identical to the results estimated. The information on judgments, estimates and assumptions that have the greatest impact on the recognition and measurement of assets, liabilities, revenues and expenses is presented below.

JUDGEMENTS

Recognition of deferred income tax assets and measurement of income tax expense

Management continually evaluates the likelihood that its deferred tax assets could be realized. This requires management to assess whether it is probable that sufficient taxable income will exist in the future to utilize these losses within the carry-forward period. By its nature, this assessment requires significant judgment. To date, Management has not recognized any deferred tax assets in excess of existing taxable temporary differences expected to reverse within the carry-forward period.

Going Concern

Evaluation of the ability of the Company to realize its strategy for funding its future needs for working capital involves making judgments. More information about the going concern assumption is disclosed in Note 2.

ESTIMATE

Impairment of exploration and evaluation assets

Determining if there are any facts and circumstances indicating impairment loss or reversal of impairment losses is a subjective process involving judgment and a number of estimates and interpretations in many cases.

When an indication of impairment loss or a reversal of an impairment loss exists, the recoverable amount of the individual asset or the cash-generating units must be estimated.

6. JUDGEMENTS, ESTIMATES AND ASSUMPTIONS (continued)

Share-based payments

The estimation of share-based payment cost requires the selection of an appropriate valuation model and consideration as to the inputs necessary for the valuation model chosen. The Company has made estimates as the volatility of its own share based on share of comparable companies, the probable life options granted and the time of exercise of those options. The model used by the Company is the Black-Scholes valuation model.

7. COMPANY ACQUISITION

On May 23, 2014, the Company acquired 100% of the equity instruments of 0957102 BC Ltd ("BC"), a British Columbia, Canada, based business, thereby obtaining control. The acquisition of BC was made to reflect the Company's position as a producer and a seller of medical marijuana in Canada.

This acquisition is considered a business combination under common control, as the two entities, Affinor Growers Inc. and BC, had a common important shareholder, as at May 23, 2014. The acquisition has been accounted by the Company prospectively from the date of obtaining the ownership interest. Assets and liabilities have been recognized upon consolidation at their carrying amounts in the IFRS financial statements of BC.

The information in the following table summarizes the consideration paid for BC and the amounts of the assets acquired and the liabilities that were recognized at the acquisition date.

On October 18, 2014, the Company and the shareholders of the acquired British Columbia private company (hereinafter "BC Ltd.") agreed to amend their original share purchase agreement. The Company gives back to the BC Ltd. shareholders all the issued and outstanding BC Ltd. shares purchased by the Company pursuant to the original share exchange agreement, in consideration for which the BC Ltd. shareholders give back to the Corporatin 2,500,000 common shares owned by Nick Brusatore a related person. In addition, the BC Ltd. shareholders have granted to the Company an irrevocable option to purchase all the issued and outstanding BC Ltd. shares which option may be exercised no later than October 18, 2017, or upon receipt by BC Ltd. Of its Medical Marijuana growers license from Helath Canada.

Consideration

2,765,000 common shares	3,818
Total Consideration paid	3,818
Recognized amounts (predecessor values)	
Assets Acquired	
Property and equipment	5,000
Cash	68
Total	5,068
Liabilities taken over	
Trade and other payables	1,250
Total	1,250
Total recognized net assets	3,818

8. OTHER RECEIVABLES

	February 28, 2015	May 31, 2014
	\$	\$
Goods and services tax receivable	40,580	44,588
Loan to a subsidary	28,828	-
Other receivables	8,112	-
	77,520	44,588

9. INVESTMENTS

The Company holds marketable securities in three quoted public companies. The investment is measured at fair value. The shares are publicly listed on a Toronto stock exchange venture and hence published price quotes are available. The aggregate amount of the investment can be summarized as follows:

	February 28, 2015	May 31, 2014
	\$	\$
Margaux Red Capital – 250,000 common shares- (Nil common shares as at May 31, 2014)	37,500	-
Chlormet Tech Inc 100,000 common shares (Nil common shares as at May 31, 2014) Geonovus Minerals Corp. — 6,000,000 common shares (Nil common shares as at May 31,	7,500	-
2014)	90,000	
Total	135,000	

(Unaudited, in Canadian dollars)

10. EXPLORATION AND EVALUATION ASSETS

	Balance as at June 1, 2014	Write-off (e)	Balance as at February 28, 2015
Quebec, Canada	\$		\$
Destor property (a)			
	1	(1)	-
Mining rights			
Exploration and evaluation expenses	-	-	-
	1	(1)	-
Joutel property (b)		()	
Mining rights	1	(1)	-
Exploration and evaluation expenses	-	-	-
	1	(1)	-
La Reine property (c)			
Mining rights	1	(1)	-
Exploration and evaluation expenses	-	-	-
	1	(1)	-
SP Property (d)			
Mining rights	1	-	1
Exploration and evaluation expenses	<u>-</u>	-	-
	1	-	1
Summary			
Mining rights	4	(3)	1
Exploration and evaluation expenses	<u> </u>	-	-
	4	(3)	1_

	Balance as at			Balance as at
	June 1, 2013	Acquisition	Write-down (e)	May 31, 2014
Quebec, Canada	\$	\$	\$	\$
Destor property (a)				
Mining rights	20,834	-	(20,833)	1
Exploration and				
evaluation expenses	-	10,119	(10,119)	-
•	20,834	10,119	(30,952)	1
Joutel property (b)	,	,	, ,	
Mining rights	60,000	246	(60,245)	1
Exploration and	,		(, -,	
evaluation expenses	-	-	-	-
'	60,000	246	(60,245)	1
La Reine property (c)	,		(, -,	
Mining rights	15,000	-	(14,999)	1
Exploration and	-,		(,===,	
evaluation expenses	-	-	-	-
'	15,000	-	(14,999)	1
SP Property (d)	-,		(,===,	
Mining rights	-	14,775	(14,774)	1
Exploration and		, -	, ,	
evaluation expenses	-	-	-	-
	-	14,775	(14,774)	1
Summary		, -	, ,	
Mining rights	95,834	15,021	(110,851)	4
Exploration and	,	-,-	, -, ,	
evaluation expenses	-	10,119	(10,119)	-
•	95,834	25,140	(120,970)	4

a) Destor Property

During the year ended August 31, 2013, the Company decided to drop the 83 mining claims of the Destor property acquired in December 2011 for 5,000 \$. In November 2012, the Company subsequently acquired 37 mining claims covering 1,593 hectares located on the same property for \$ 2,334.

On February 28, 2013, the Company signed an agreement to acquire Destor Extension property in exchange for the issuance of 925,000 common shares. The Destor extension property is composed of 4 mining claims covering an area of 144 hectares located in Destor County. During the period, the Company decided to not renew the mining claims.

b) Joutel property

On August 31, 2012, the Company signed an agreement to acquire the Joutel property for \$ 10,000 in cash and 1,000,000 common shares. The Company paid these amounts in October 2012. The Joutel property is composed of 11 mining claims covering an area of 273 hectares located in the Joutel township In Abitibi, Quebec. During the period, the Company decided to not renew the mining claims.

Notes to financial statements

For the nine-month periods ended February 28, 2015 and 2014

(Unaudited, in Canadian dollars)

10. EXPLORATION AND EVALUATION ASSETS (continued)

c) La Reine property

On February 28, 2013, the Company signed an agreement to acquire the La Reine property in exchange of the issuance of 750,000 common shares. The Joutel property is composed of 2 mining claims covering an area of 85 hectares located 25km from the old mine Dovan-Copper. During the period, the Company decided to not renew the mining claims.

d) SP property

On June 13, 2013, the Company signed an agreement to acquire the SP property in exchange of the issuance of 985,000 common shares. The property is composed of 7 mining claims covering 326 hectares.

e) Write-down

Since the Company has not planned for an exploration budget on these properties and management has chosen to focus on the company's culture-related activities, an impairment was recognized in net earnings during the year ended May 31, 2014 and the nine-month period ended February 28, 2015.

11. PROPERTY AND EQUIPMENT

	Greenhouse	Computer euipment	Office equipment	Land	Building	Total\$
Gross carrying amount						
Balance at June 1, 2014	-			-	-	-
Acquisition	811,024	4,033	5,683	163,200	176,800	1,160,920
Balance at February 28, 2015	811,024	4,033	5,683	163,200	176,800	1,160,920
Accumulated depreciation and impairment						
Balance at June 1, 2014				-	-	-
Amortization		318	578		4,151	5,047
Balance at February 28, 2015	811,024	318	578		4,151	5,047
Carrying amount at February 28, 2015	811,024	3,716	5,285	163,200	172,649	1,155,874
12. INTANGIBLE ASSETS						
				Lic	ense \$	Total \$
Gross carrying amount						
Balance at June 1, 2014					-	-
Acquisition				723	3,888	723,888
Balance at February 28, 2015				723	3,888	723,888
Accumulated depreciation and impairment						
Balance at June 1, 2014					-	-
Amortization				2	1,253	21,253
Balance at February 28, 2015				21	1,253	21,253
Carrying amount at February 28, 2015				702	2,635	702,635

Notes to financial statements

For the nine-month periods ended February 28, 2015 and 2014

(Unaudited, in Canadian dollars)

13. INVESTMENT ACCOUNTED FOR USING THE EQUITY METHOD

The Company holds through its wholly owned subsidiary Affinor Analytics LLC. a 49% (nil at May 31, 2014) equity interest in Herbal analytics LLC. The investment is accounted for using the equity method.

The aggregate amount of the associate can be summarized as follows:

	February 28, 2015	May 31, 2014
	\$	\$
Assets	539,507	-
Liabilities	116,323	-
Revenues	-	-
Net loss	128,390	-
Loss attributable to the Company	62,911	-

During the quarter the Company abandoned its involvment in the sale and grow medical cannabis industry.

14. EQUITY

14.1 Share Capital

Authorized share capital:

Unlimited numbers of common shares voting and participating, with no par value.

- a) On June 17, 2013, the Company acquired the SP Property. The SP property contains 7 mining claims and covers 325 hectares. According to the terms of the transaction, the Company acquires 100 % of the 7 claims in exchange of the issuance of 985,000 common shares of the Company.
- b) On June 17, 2013 the Company closed a non brokered private placement in the amount of \$ 96,500, through the sale of 6,433,333 common shares priced at 0.015 \$ each. Approximately 49 % of the common shares were acquired by directors and officers of the Company. The Company was granted an exemption to the CNSX minimum price rule.
- c) On July 31, 2013, the Company closed the second tranche of a non brokered private placement in the amount of 32,250 \$, through the sale of 2,150,000 common shares priced at 0.015 \$ each. Approximately 23 % of the common shares were acquired by the president and chief executive officer of the Company. The Company was granted an exemption to the CSE minimum price rule.
- d) On July 31, 2013 the Company entered into an agreement to early convert the \$ 295,751 convertible debenture as well as its accrued interest of \$ 14,915 by the issuance of 6,213,320 common shares at a deemed price of \$ 0.05 per share.
- e) On March 28, 2014, the Company entered into an agreement for debt settlement of \$153,500 payable to directors with shares. The Company issued 614,000 common shares at a deemed price of \$0.25 per share. The Company recorded a loss on settlement of financial liability of \$55,260 in the statement of changes in equity.
- f) On April 4, 2014, the Company announced the closing of the first tranche of a non-brokered private placement for gross proceeds of \$ 1,007,659. The securities issued are composed of 4,030,636 units. Each unit is comprised of one common share and one share purchase warrant of the Company. The common share purchase warrant has a term of two three-month period exercisable at \$ 0.40 with an early exercise provision when the common shares of the Company trade above \$ 0.75 for 20 consecutive trading days. The Company paid a finder's fee of \$ 35,023 and issued 140,090 broker warrants. Each broker warrant entitling to acquire one common share of the Company at a price of \$ 0.40 with an early exercise provision when the common shares of the Company trade above \$ 0.75 for 20 consecutive trading days.
- g) On April 14, 2014, the Company appointed Nick Brusatore to its advisory board. The Company has issued 10,000,000 common shares of the company to Mr. Brusatore to prepare and execute the business model and financial plan required for the full-scale, mass production of marijuana for medical purposes. For the issued of the 10,000,000 common shares, the Company have recorded an expense of \$3,800,000 included in Management fees. Mr. Brusatore will also receive an additional compensation of 5,000,000 common shares when the Company is granted its licence for production. The Company has granted 1,000,000 stock options to Mr. Brusatore to purchase common shares of the Company at an exercise price of \$ 0.49 per share. The Company has agreed to pay a 10% finder's fee, payable in shares (1,000,000 common shares), to Michael Flowerdew for facilitating the agreement with Mr. Brusatore. This compensation resulted in an expense of \$380,000 recorded in professional fees and consulting fees.
 - On May 5, 2014, the company and Nick Brusatore agreed to cancel the additional compensation of 5,000,000 common shares. This cancelation resulted in an additional expense recorded as Management fees of \$ 2,100,000.
 - The fair value of the service received by reference to the shares using the quoted price of the day of insuance or cancelation because the fair value of the service could not be estimated reliably.
- h) On April 23, 2014, the Company closed a second and final tranche of a non-brokered private placement for gross proceeds of \$1,526,750. The securities issued are composed of 6,107,000 units. Each unit is comprised of one common share and one share purchase warrant of the Company. The common share purchase warrant has a term of two three-month period exercisable at \$0.40 with an early exercise provision when the common shares of the Company trade above \$0.75 for 20 consecutive trading days. The Company issued 130,030 broker warrants. Each broker warrant entitling to acquire one common share of the Company at a price of \$0.40 with an early exercise provision when the common shares of the Company trade above \$0.75 for 20 consecutive trading days. The Company paid finder fees and other share insurance cost of \$47,408.
- i) On May 23, 2014, the Company acquired 100% of a private company in the final stage of obtaining their medical marijuana license. The Company is located in the province of British Columbia. The company issued 2,765,000 common shares and will issue 2,435,000 common shares when the issuance of a licence to D&G.

Notes to financial statements

For the nine-month periods ended February 28, 2015 and 2014

(Unaudited, in Canadian dollars)

14. EQUITY (continued)

14.1 Share Capital (continued)

- j) On June 24, 2014, the Company concludes an agreement for the exclusive technology license with Vertical Designs Ltd. ("VDL") a company under control of a director and an important shareholder of the Company. Under the terms of the agreement, the Company issued 666,666 common shares at a deemed price of \$ 0.75 per share to VDL and will pay a 5% royalty on the net sales of production.
- k) On September 23, 2014, the Company acquired a 49% interest in Herbal Analytics, a Washington State testing laboratory. Under the term of the agreement, the Company paid \$ 150,000, \$ 150,000 in a repayable loan over a maximum of 4 three-month period and issued 949,612 common shares.
- I) In September 2014, 255,000 warrants were exercised for a cash consideration of \$ 102,000. The fair value of \$ 23,942 assigned to these warrants has been reclaim field from warrants to share capital.
- m) In September 2014, 34,955 brokers warrants were exercised for a cash consideration of \$ 13,982.
- n) On October 18, 2014, the Company and the D&G shareholders agreed to cancel the original agreement. The Company sells back to the D&G shareholders all the issued and outstanding D&G shares purchased by the Company pursuant to original share exchange agreement, in consideration for which the D&G shareholders sell back to the Company 2,550,000 common shares. The D&G shareholders grant to the Company an irrevocable option to purchase all the issued and outstanding D&G shares which option may be exercised no later than October 18, 2017.
- On October 22, 2014, the company entered into an exclusive patent license agreement with Vertical Designs Ltd ("VDL") to become the commercial licensor of VDL patented, food growing technology on a worldwide territory excluding only Ontario, Alberta and the Maritimes (the «Territory»). Under the terms of the agreement, the Company will use VDL's technology to produce high quality non-GMO fruits and vegetables, royalty free to VDL. An initial entry fee is paid to VDL by the issuance of 722,222 common shares of the Company. Also under the agreement, the Company will be able to sublicense VDL's technology for fruits and vegetables to any other company of facility on the territory and receive a royalty on sub-licensed production. The Company will receive 50% of any fee or royalty paid to it by any sublicensee of the VDL technology, the other portion being paid to VDL.
- p) On December 1, 2014, the Company cancelled the investor relations agreement with Sigorex Management GMBH entered into on September 26, 2014.
- q) On December 1, 2014, the Company engaged Secure Strategy Group for financial and corporate advisory services. Under the terms Secure Strategy Group will receive a monthly cash advisory fee of \$ 8,000 US and 1,000,000 warrants of the Company that are exercisable into 1,000,000 common shares of the Company at an exercise price of \$0.32 per share on or before October 16, 2017.
- r) On December 2, 2014, the Company appointed Pierre C. Miron as VP Finance, CFO & Director. Under the terms, Mr. Miron will receive 300,000 incentive stock options to purchase common shares. The options are exercisable on or before December 1, 2017, at an exercise price of \$ 0,22 per share.
- s) On December 18, 2014, the Company closed the Definitive Agreement of the previously announced LOI on November 4, 2014 with North Country Natural Solutions LLC ("North Country") and Iroquois Consulting Group LLC ("Iroquois") in New York State. It represents a \$500,000.00 sublicensing agreement and 5% royalty on the net sales on the food production. Additionally North Country and Iroquois will offer consulting services to represents exclusively the Company with all the native Communities in the United States in the agriculture and cannabis sectors with the objective to become leader and a model in both industry.
- t) December 19, 2014, the Company hired Hugh Bowman as Advisor. Under the terms of the agreement, M. Bowman will receive 300,000 incentive stock options to purchase common shares. The options are exercisable on or before December 18, 2017, at an exercise price of \$ 0.25 per share.
- u) January 5, 2015, Herbal Analytics LLC signed a 2 year contract to be the cannabis laboratory for Green Color and Arches (GC&A), a producer of medical products. GC& A has agreed to engage Herbal Analytics to exclusively study their cannabis for compound research and drug discovery purposes. Within the terms of the Agreement, Herbal Analytics will also provide services.
- v) January 13, 2015, the Company completed the acquisition and ownership, development and commercialization rights of the farming technology "Method and Apparatus for Automated Horticulture and Agriculture" Patent from Vertical Designs Ltd ("VDL"). Under the terms of the agreement, the Company becomes the patent holder and will issue to VDL in consideration of 5,000,000 common shares at a price of \$0.20 per share.
- w) January 27, 2015, the Company signed a consulting services agreement with the consulting firm PRC Partners ("PRC") Ltd. Under the term PRC will receive 1,500,000 common shares of the Company and 500,000 stock options exercisable at \$ 0.15 per shares on or before July 28, 2015.
- x) February 11, 2015, the Company closed a non-broken private placement for gross proceds of \$105,000. The securities issued are composed of 700,000 units. Each unit is comprised of one common share and one share purchase warrant of the Company. The common share purchase warrant has a term of 24 month exercisable at \$ 0.30.
- y) February 19, 2015, the Company announced that it has entered into a \$ 30 million US equity line facility agreement with Dutchess Opportunity Fund II, a Delaware limited partnership.

Notes to financial statements

For the nine-month periods ended February 28, 2015 and 2014

(Unaudited, in Canadian dollars)

14. EQUITY (continued)

14.2 Warrants

Outstanding warrants are as follows:

		February 28, 2015		May 31, 2014
	Number of warrants	Weighted average exercise price	Number of warrants	Weighted average exercise price
	\$	\$	\$	\$
Balance, beginning of the period	10,137,636	0.40	4,800,000	0.10
Issued private offerings	2,700,000	0.31	10,137,636	0.40
Exercised	(2,655,000)	0.40	-	-
Expired warrant	-	-	(4,800,000)	0,10
Balance, end of the period	10,182,636	0.38	10,137,636	0,40

The number of warrants outstanding exercisable in exchange for an equivalent number of shares is as follows:

		February 28, 2015		May 31, 2014
Expiration date	Number	Exercise price	Number	Exercise price
•		<u> </u>		\$
April 4, 2016	635,000	0.40	635,000	0.40
April 7, 2016	3,045,636	0.40	3,395,636	0.40
April 11, 2016	1,080,000	0.40	1,080,000	0.40
April 14, 2016	564,000	0.40	564,000	0.40
April 16, 2016	178,000	0.40	218,000	0.40
April 22, 2016	360,000	0.40	360,000	0.40
April 23, 2016	1,620,000	0.40	3,885,000	0.40
February 12, 2017	700,000	0.30	-	-
October 16, 2017	2,000,000	0.32	-	-
	10,182,636	0.38	10,137,636	0,40

The underlying expected volatility was determined in reference to historical data of three comparable companies over the expected life period.

The fair value of warrants was calculated using the Black-Scholes option pricing Model and the following weighted average assumptions:

	February 28, 2015	May 31, 2014
	\$	\$
Expected life	2,74 years	2 years
Risk-free interest rate	11.93 %	1.08%
Expected volatility	125%	125%
Expected dividend	-	-
Share price at date of issuance	0,27	0.36

14.3 Broker's warrants

Outstanding broker's warrants are as follows:

		February 28, 2015		May 31, 2014
	Number of brokers warrants	Weighted average exercise price	Number of brokers warrants	Weighted average exercise price
		\$		\$
Balance, beginning of the period	270,390	0.40	-	-
Exercised	(54,925)	0.40	-	-
Issued private offerings	<u></u>	<u> </u>	270,390_	0.40
Balance, end of the period	215,465	0.40	270,390	0.40

The number of broker's warrants outstanding exercisable in exchange for an equivalent number of shares is as follows:

		February 28, 2015		May 31, 2014
Expiration date	Number	Exercise price	Number	Exercise price
·		\$		\$
April 4,2016	85,165	0.40	140,090	0.40
April 14, 2016	108,000	0.40	108,000	0.40
April 16, 2016	13,800	0.40	13,800	0.40
April 23, 2016	8,500	0.40	8,500	0.40
	215,465		270,390	

Notes to financial statements

For the nine-month periods ended February 28, 2015 and 2014

(Unaudited, in Canadian dollars)

14. EQUITY (continued)

14.3 Broker's warrants (continued)

The fair value of the broker's warrants was calculated using the Black-Scholes option pricing model and the following weighted average assumptions:

The underlying expected volatility was determined in reference to historical data of three comparable companies over the expected life period:

	February 28, 2015	May 31, 2014
Expected life	-	2 years
Risk-free interest rate	-	1.065%
Expected volatility	-	125%
Expected dividend	-	-
Share price at date of issuance	-	0.36

14.4 Share-based payments

The Company maintains a share-based payment plan (the "Plan") whereby the Board of Directors may from time to time grant to employees, staff members and consultants, options to acquire common shares in such numbers, for such terms and at such exercise prices as may be determined by the Board but cannot be lower than the discounted price.

The plan provides that the maximum number of common shares in the capital of the Company which may be reserved for issuance under the plan may not exceed 10 % of the publicly traded shares issued and outstanding on the grant date of the options (on a non-diluted basis), this number being equal to 6,757,588 shares on February 28, 2015.

Options granted are exercisable at the day of grant except for persons performing investor relations activities. Options granted to supplier of investor's relations services must at a minimum vest in stages over a period not less than 12 months with no more than one fourth of the options vesting in any three-month period.

A summary of changes in the Company's common share purchase options is as follows

		February 28, 2015		May 31, 2014
	Number of options outstanding and exercisable	Weighted average exercise price	Number of options outstanding and exercisable	Weighted average exercise price
		\$		\$
Balance, beginning of the period	4,620,000	0.26	=	-
Granted	3,000,000	0.40	5,620,000	0.23
Exercised	(1,470,000)	0.16	(1,000,000)	0.10
Balance, end of the period	6,150,000	0.37	4,620,000	0.26
				February 28, 2015
Nu	mber	Exercise price		Weighted remaining life
		\$		
	0,000	0.10		3.24
	0,000	0,22		2.83
	0,000	0.25		3.50
	0,000	0.30		4.92
400	0,000	0.33		4.15
300	0,000	0.35		4.11
300	0,000	0.40		4.67
300	0,000	0.47		4.43
1,350	0,000	0.49		4.19
· ·	0.000	0.67		4.33
	0,000	0.71		4.30
	0,000	0.80		4.33
300	0,000	0.85		4.26
100	0,000	1.03		4.26
6,150	0,000	0.36		

Notes to financial statements

For the nine-month periods ended February 28, 2015 and 2014

(Unaudited, in Canadian dollars)

14. EQUITY (continued)

14.4 Share-based payments (continued)

May 31, 2014

Number	Exercise price	Weighted remaining life
	\$	
250,000	0.05	4.73
1,920,000	0.10	4.49
400,000	0.33	4.88
600,000	0.35	4.86
1,000,000	0.49	4.95
350,000	0.49	4.95
100 000	0.80	5.00
4,620,000	0.26	-

The Company granted 3,000,000 stock options during the nine-month period ended February 28, 2015 (nil in 2013) to directors and consultants. The fair value of these options is of \$1,407,117 (\$ nil in 2013) was estimated using the Black-Scholes option pricing model with the following assumptions:

The weighted average share price at the date of exercise was \$ 0.52.

The underlying expected volatility was determined by reference to historical data of three comparable companies over the expected life period.

	February 28, 2015	May 31, 2014
	\$	\$
Risk-free interest rate	33,41 %	1.675 %
Expected volatility	125 %	125 %
Expected life	3,78 years	5 years
Expected dividend	-	-
Fair value of options granted	0.40	0.16
Share price at date of grant	0.40	0.19

15 RELATED PARTY TRANSACTIONS

Related party transactions were recorded at the exchange value, which is the consideration determined and agreed to by the related parties.

The Company's related parties include directors, key management and companies controlled by directors and key management, as described below.

Unless otherwise stated, none of the transactions incorporated special terms and conditions and no guarantees were given or received. Outstanding balances are usually settled in cash.

15.1 Transactions with key management personnel

Key management of the Company are members of the Board of Directors. Key management compensation allocated includes the following expenses:

	For the three-month period ended February 28		For the nine-month period ended February 28	
	2015	2014	2015	2014
	\$	\$	\$	\$
Short-term key management benefits				
Social security cost	2,374	-	8,909	-
Salaries	48,000	-	135,936	-
Professional fees	14,000	10,209	56,000	20,526
Others	3,079	-	7,544	-
Total short-term management benefits	67,453	10,209	208,389	20,526
Management fees	75,000	-	225,000	-
Consulting fees	36,666	27,000	131,664	46,298
Share-based payments	33,949	<u>-</u>	216,952	
Total remuneration	213,068	37,209	782,005	66,824

In addition, the Company has a payable of \$36,149 in consulting and management fees to companies controlled by directors of the Company as at February 28, 2015.

Notes to financial statements

For the nine-month periods ended February 28, 2015 and 2014

(Unaudited, in Canadian dollars)

16. ASSETS AND FINANCIAL LIABILITIES

Categories of assets and liabilities

The carrying value and fair value of financial instruments presented in the statement of financial position are as follows:

		February 28, 2015		May 31, 2014	
	Book value	Fair value	Book value	/ Fair value	
	\$	\$	\$	\$	
Financial assets					
Loans and receivables					
Cash	64,198	64,198	1,944,644	1,944,644	
Other receivable	1,015	1,015	175	175	
Investments	135,000	135,000	-	-	
	200,213	202,213	1,944,819	1,944,819	
Financial liabilities					
Trade and other payables	338,298	338,298	249,850	249,850	

The fair value of the liability component of the convertible debenture was determined by discounting future cash flows at an interest rate the Company could obtain on the market. It is the rate the Company would obtain for financial liabilities with similar conditions and maturity.

17 LOSS PER SHARE

Both the basic and diluted loss per share have been calculated using the net loss as a numerator, i.e. no adjustment to the net loss was necessary for the periods presented.

In calculating the diluted loss per share, dilutive potential common shares such as share options, warrants and the conversion option on the convertible debenture have not been included as they would have the effect of decreasing the loss per share. Decreasing the net loss per share would be antidilutive. Details on the share options and the warrants with a potentially dilutive effect on earnings per share are presented in note 14.

18 ADDITIONAL INFORMATIONS CASH FLOWS

	For the three-month period ended February 28		For the nine-month period ended February 28	
	2015	2014	2015	2014
	\$	\$	\$	\$
Other Receivables	121,409	(2,834)	(47,792)	8 696
Prepaid expenses	(53,800)	4,190	59,507	-
Trade and other payables	(359,958)	100,928	88,448	91 246
Total	(292,349)	102,284	100,163	99 942

19. INFORMATION DISCLOSURE ABOUT CAPITAL

The Company monitors capital on the basis of the carrying amount of equity and convertible debenture. The capital is \$ 2,738,590 as at February 28, 2015 (\$ 1,914,999 as at May 31, 2014).

The objective of the Company's capital management is to preserve its ability to continue its operations, its program of acquisition and is agriculture operations. This objective will be achieved by identifying the right exploration and agriculture projects, adding value to these projects and ultimately taking them through to production or sale and cash flow, either with partners or by the Company's own means.

The Company is not subject, under external rules, to capital requirements.

When financing conditions are not optimal, the Company may enter into option agreements or other solutions to continue its activities or may slow its activities until conditions improve.

20. FINANCIAL RISK MANAGEMENT

The Company is exposed to various risks related to financial instruments. The financial assets and liabilities of the Company are summarized by category in note 16. The main types of risks to which the Company is exposed are market risk, credit risk and liquidity risk.

No change has been made in terms of objectives, policies or procedures related to the management of risks arising from financial instruments during periods of financial reporting considered.

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. The Company is exposed to interest rate risk. The objectives of the Company are to ensure cash inflows in the short and medium term, while reducing exposure to capital markets. The Company does not trade in financial assets for speculative purposes.

The main financial risks to which the Company is exposed are detailed below:

Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting obligations associated with financial liabilities that are settled by delivering cash or another financial assets.

Notes to financial statements

For the nine-month periods ended February 28, 2015 and 2014

(Unaudited, in Canadian dollars)

20. FINANCIAL RISK MANAGEMENT (continued)

The Company manages its liquidity risk by using budgets that enable it to determine the amounts required to fund its obligations.

As at February 28, 2015, all of the Company's financial liabilities have contractual maturities of less than 30 days and are subject to normal trade terms. As at February 28, 2015, the Company presents a working capital of \$ 235,151. The ability of the Company to continue its activities relies upon the supports of its suppliers and obtaining additional financing.

Credit risk

Credit risk results from the possibility that a loss may occur from the failure of another party to perform according to the terms of the contract. Cash are held with a Canadian chartered bank which reduces the risks. Also the Company continuously menitors defaults of others parties. No impairment loss has been recognized on the periods presented.

The Group's management considers that all financial assets that are not impaired or past due for each of the reporting dates under review are of good credit quality.

Foreign currency sensitivity

The Company is exposed to currency risk arising from exchange rate fluctuations against its reporting Canadian currency. Currency transaction risk is the impact of exchange rate fluctuations on the Company Income Statement, which is the effect of currency rates on expected future cash flows and investments. The Company policy will be to mitigate this is to hedge 50% of the forecast major currency cash flows for 12 months and to maintain bank account in currency to offset revenue and expenses in the same currency. The principal foreign exchange transaction exposure comprises both the geographical location of our sales of licence in the USA and the sourcing of raw material, labour and overhead office being in Canadian dollar.

21. COMMITMENTS

In December 2013, the Company signed a service contract, with a company controlled by one of the officers of the Company, for consulting and financial services for an annual amount of \$ 123,000 for the first year and \$ 150,000 for the second year. This agreement started on December 1st, 2013 and will end on November 30, 2015. On February 28, 2015, the balance of this commitment was \$ 112,500.

In October 2014, the Company signed a contract for a consulting service for an amount of \$ 96,000 US. On February 28, 2015, the balance of this commitment was \$ 51,000 US.

In October 2014, the Company signed a contract for consulting services for an amount of \$ 96,000 US. This agreement started on October 1st, 2014 and will end on April 30, 2015. On February 28, 2015, the balance of this commitment was \$ 16,000 US.

22. EVENT AFTHER THE REPORTING PERIOD

March 18, 2015, the Company annonced that is Subsisiary Affinor Analytics signed an exclusive service agreement with MediGrow. Under the term MediGrow will pay \$ 3,000 US per month for the first six months, \$ 6,500 for the next 18 months. Extra charges include mainly 325 US per hour for data consulting billed on separate invoice and also to be paid monthly.

March 26, 2015, the Company announced that Squamish Nation hereditary Chief Gilbert Jacop has joined Affinor's advisory board.

April 10, 2015, the Company announced that they amicably resolve the Washington litigation to dismiss the case with prejudice with Abattis Bioceuticals Corp.